The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDCC Regulatory News (DCC)

Share Price Information for DCC (DCC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5,670.00
Bid: 5,660.00
Ask: 5,670.00
Change: -70.00 (-1.22%)
Spread: 10.00 (0.177%)
Open: 5,640.00
High: 5,675.00
Low: 5,595.00
Prev. Close: 5,740.00
DCC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DCC Healthcare acquires Ion Laboratories

12 Nov 2019 07:00

RNS Number : 0387T
DCC PLC
12 November 2019
 

 

 

12 November 2019

 

 

DCC Healthcare announces acquisition of Ion Laboratories

 

DCC plc, the leading international sales, marketing and support services group, announces that DCC Health & Beauty Solutions has acquired Ion Laboratories, Inc ('Ion'), a provider of contract manufacturing and related services to the growing health supplements and nutritional products market in the US.

 

The acquisition of Ion follows the acquisition of Elite One Source in February 2018 and will significantly enhance DCC Health & Beauty Solutions' service offering to customers in the US market. Ion has a broad product format capability encompassing tablets, capsules, powders and liquids across a variety of product categories including herbal and botanical products, probiotics and liquid nutritionals. Ion is currently commissioning a new nutritional gummies manufacturing line which will provide DCC Health & Beauty Solutions with capability in this fast growth category. Ion's customer base largely consists of specialty brand owners and its service offering includes product development, formulation, manufacturing, packaging and regulatory services.

 

Ion's well-invested facilities in Largo, Florida extend to 350,000 square feet and provide capacity to meet its organic growth plans. The facilities comply with FDA cGMP (current Good Manufacturing Practices) and Health Canada standards and are certified by leading third-party regulatory bodies, including NSF and USDA Organic. The business is led by an experienced management team, employs 360 people and has revenues of approximately $80 million.

 

The consideration was based on an enterprise value of approximately $60 million (£46 million), most of which was paid in cash on completion.

 

 

Donal Murphy, Chief Executive of DCC plc, said today:

 

"DCC Health & Beauty Solutions provides high-quality services to leading health and beauty brand owners, specialist retailers and direct sales organisations. The acquisition of Ion significantly enhances our presence in the US market and Ion will work closely with both Elite One Source and DCC Health & Beauty Solutions' European businesses to cross-sell the full breadth of the Group's comprehensive offering for health & beauty brands.

 

The US is the world's largest health supplements and nutritional products market. It is also an innovative, high-growth market, with a fragmented contract manufacturing base. We continue to be excited by the significant opportunities for organic and acquisitive growth in this market."

 

 

 

For reference:

Donal Murphy, Chief Executive

Conor Costigan, Managing Director, DCC Healthcare

Kevin Lucey, Head of Capital Markets

 

Telephone: +353 1 2799400

Email: investorrelations@dcc.ie

Web: www.dcc.ie

 

Powerscourt (Media)

Lisa Kavanagh / Victoria Palmer-Moore

Telephone: +44 20 7250 1446

Email: DCC@powerscourt-group.com

 

About DCC plc

DCC is a leading international sales, marketing and support services group with a clear focus on performance and growth. It operates through four divisions: LPG, Retail & Oil, Technology and Healthcare.

 

DCC is an ambitious and entrepreneurial business operating in 20 countries, supplying products and services used by millions of people every day. Building strong routes to market, driving for results, focusing on cash conversion and generating superior sustainable returns on capital employed enable the Group to reinvest in its business, creating value for its stakeholders.

 

Headquartered in Dublin, employing approximately 12,700 people, DCC's four divisions are:

·; DCC LPG - a leading LPG sales and marketing business with operations in Europe, the US and Asia and a developing business in the retailing of natural gas and electricity;

·; DCC Retail & Oil - a leader in the sales, marketing and retailing of transport fuels and commercial fuels, heating oils and related products and services in Europe;

·; DCC Technology - a leading route-to-market and supply chain partner for global technology brands and customers; and

·; DCC Healthcare - a leading healthcare business, providing products and services to healthcare providers and health and beauty brand owners.

 

DCC plc is listed on the London Stock Exchange and is a constituent of the FTSE 100. In its financial year ended 31 March 2019, DCC generated revenue of £15.2 billion and operating profit of £460 million.

 

DCC has an excellent record, delivering compound annual growth of 14% in operating profit and generating an average return on capital employed of approximately 19% over 25 years as a public company.

 

 

About DCC Healthcare

DCC Healthcare is a leading healthcare business, providing products and services to healthcare providers and health and beauty brand owners. DCC Healthcare operates through two businesses, DCC Vital and DCC Health & Beauty Solutions. DCC Vital markets and sells medical and pharmaceutical products to healthcare providers across all sectors of the healthcare market in the UK and Ireland. DCC Health & Beauty Solutions builds long-term partnerships with international brand owners, providing specialist services including product development, formulation, manufacturing and packaging.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ACQGGGQGGUPBGBG
Date   Source Headline
24th May 20139:58 amRNSHolding(s) in Company
22nd May 201312:50 pmRNSTreasury Shares
20th May 20131:02 pmRNSTreasury Shares
14th May 20137:00 amRNSPreliminary Results for year ended 31 March 2013
7th May 20133:18 pmRNSHolding(s) in Company
7th May 20133:06 pmRNSHolding(s) in Company
7th May 20132:50 pmRNSHolding(s) in Company
7th May 20137:00 amRNSMSM - Cancellation Notice
17th Apr 20133:51 pmRNSHolding(s) in Company
12th Apr 20135:10 pmRNSHolding in Company TR-1
11th Apr 20135:25 pmRNSHolding in Company TR-1
4th Apr 20134:24 pmRNSHolding in Company TR-1
4th Apr 20134:21 pmRNSHolding in Company TR-1
22nd Mar 20134:40 pmRNSHolding in Company
19th Mar 20133:05 pmRNSHolding in Company TR-1
15th Mar 20133:55 pmRNSHolding in Company TR-1
6th Mar 20135:45 pmRNSHolding in Company TR-1
1st Mar 20134:00 pmRNSHolding in Company TR-1
28th Feb 20133:36 pmRNSTotal Voting Rights
27th Feb 20137:00 amRNSDCC completes acquisition
26th Feb 20134:41 pmRNSTreasury Shares
26th Feb 20137:00 amRNSChange in listing arrangements
18th Feb 20134:08 pmRNSTreasury Shares
8th Feb 20135:27 pmRNSTreasury Shares
8th Feb 20138:32 amRNSDirector Declaration
6th Feb 201312:16 pmRNSTreasury Shares
6th Feb 20137:00 amRNSInterim Management Statement
5th Feb 20139:38 amRNSHolding in Company TR-1
23rd Jan 20133:02 pmRNSMerger Update
4th Jan 201310:38 amRNSHolding in Company - TR1
20th Dec 201210:24 amRNSDCC Healthcare Acquisition of Kent Pharmaceuticals
11th Dec 20121:06 pmRNSHolding(s) in Company
10th Dec 20127:00 amRNSDCC completes acquisition
30th Nov 20122:54 pmRNSVoting Rights and Capital
27th Nov 20124:09 pmRNSHolding in Company
27th Nov 20124:06 pmRNSHolding in Company
20th Nov 20122:44 pmRNSTreasury Shares
14th Nov 20125:21 pmRNSDirector/PDMR Shareholding
14th Nov 20123:36 pmRNSTreasury Shares
12th Nov 20124:57 pmRNSDirector/PDMR Shareholding
6th Nov 20127:00 amRNSInterim Results Six Months ended 30 September 2012
5th Nov 20124:03 pmRNSDCC plc Board Retirement
1st Nov 20127:00 amRNSDCC completes the acquisition of Benegas
31st Oct 20124:00 pmRNSMerger Update
24th Oct 201211:10 amRNSHolding in Company - TR 1
19th Oct 201211:00 amRNSMerger Update
1st Oct 20127:00 amRNSDCC completes acquisition
28th Sep 20121:00 pmRNSTotal Voting Rights
21st Sep 20128:00 amRNSDCC to expand LPG business into the Benlux region
18th Sep 20125:35 pmRNSHolding in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.